Heart Failure – an Evolving Landscape: Evidence-based approaches to the management of HFpEF 

Published: 07 October 2021

  • Views:

    Views Icon 355
  • Likes:

    Heart Icon 2

Overview

Full programme

  • Views:

    Views Icon 355
  • Likes:

    Heart Icon 2

Overview

In this second roundtable of the series, we consider the recent dramatic advances to the management of HFpEF. 

 

Prof Andrew Coats is joined by Dr Shelley Zieroth, Dr Javed Butler and Prof Stefan Anker for their assessment of the current treatment landscape following the publication of EMPEROR-PRESERVED. During this roundtable they discuss current unmet needs in HFpEF, the recent advances in HFpEF treatment, the importance of EF in relation to treatment selection and, in the final session, consider how to best implement empaglifozin in the real world.

 

 

Supported by the Boehringer Ingelheim & Lilly Alliance

Series overview

Part 1

Unmet needs in patients with HFpEF

1 session

  • Unmet needs in patients with HFpEF

    Watch now

Part 2

New therapy advancements in HFpEF

1 session

  • New therapy advancements in HFpEF

    Watch now

Part 3

Unlocking clinical success of SGLT-2 inhibition in HFpEF

1 session

  • Unlocking clinical success of SGLT-2 inhibition in HFpEF

    Watch now

Part 4

Application of using SGLT-2 inhibitors in HFpEF

1 session

  • Application of using SGLT-2 inhibitors in HFpEF

    Watch now

Faculty biographies